Therapeutic principles and indications of ruxolitinib/ruxolitinib cream

Ruxolitinib cream (Ruxolitinib) is an emerging topical preparation for the treatment of skin diseases in recent years. Its core principle is based on the regulation of the JAK-STAT signaling pathway and is an important breakthrough in modern precision medicine in the field of dermatology. Ruxolitinib is a selective JAK1/JAK2 inhibitor that can block the signal transduction of multiple inflammatory mediators, thereby regulating immune overactivity and effectively relieving inflammation, itching, erythema and other symptoms.

Under normal immune conditions,JAK-STAT pathway is responsible for transmitting external stimulus signals through cells, triggering the release of relevant cytokines and immune responses. However, in some skin diseases, such as vitiligo and atopic dermatitis, this pathway is abnormally activated, leading to continued local or systemic inflammation. Ruxolitinib cream targets the lesion through topical application, inhibits the excessive conduction of abnormal signals, and improves skin condition.

Currently, the U.S.FDA has approved ruxolitinib cream for the treatment of moderate to severe atopic dermatitis (AD) and non-segmental vitiligo associated with depigmentation of the face or body 12 years and older. Compared with traditional treatment methods, such as hormone drugs or calcineurin inhibitors, ruxolitinib has higher targeting and lower systemic absorption rate. It is especially suitable for long-term maintenance phase and treatment of facial lesions, and can significantly reduce the risk of side effects. In addition, ongoing research is also exploring its potential application in psoriasis, seborrheic dermatitis and other chronic inflammatory skin diseases, and the scope of indications is expected to be further expanded in the future.

It is worth noting that the principle of ruxolitinib cream in treating vitiligo is not to directly promote pigment production, but to reduce the local inflammatory environment, block the attack on melanocytes, and provide a stable foundation for pigment cell regeneration. This mechanism of action has significant advantages for patients with vitiligo whose core cause is immune disorder, and is especially suitable for people with active vitiligo or facial vitiligo.

Reference: https://www.opzelura.com/